Objective(s): MicroRNAs (miRNAs) are considered as powerful, post-transcriptional regulators of gene expression in hepatocellular carcinoma cells (HCC). However, the function of miR-92a is still unclear in HCC. Materials and Methods: Expression of miR-92a in human HCC cell lines was evaluated using qRT-PCR. MTT assay and transwell assay were used to examine the function of miR-92a in HepG2 and Huh7 cells. Bioinformatic analyses and luciferase reporter assays were used to validate FOXA2 as a direct target gene of miR-92a. Consistently, the biological outcome of miR-92a on regulating FOXA2 was examined by proliferation and invasion analysis in vitro. Results: Here, we detected the higher expression of miR-92a in human HCC cell lines, such as HepG2, Huh7 and Hep3B, compared with the normal human hepatocyte L02 cells. Overexpression of miR-92a significantly increased cell growth and invasion ability, while the knockdown of miR-92a could remarkably inhibit the growth and invasion possibility. We identified that miR-92a has specific targeting sites in the 3'-UTR of the FOXA2. By overexpressing miR-92a in HepG2 cells or Huh7 cells, the expression of FOXA2 was remarkably repressed. Conclusion: We demonstrated that miR-92a may play a critical role in HCC proliferation and invasion and may serve as a novel therapeutic target by the repression of FOXA2. 
Introduction
Hepatocellular carcinoma (HCC) is one of the most important malignant tumor, which causes highly cancer-related mortality all over the world (1) , especially in China (2) . Duri ng the development of HCC, mul tiple genes are deregulated, and oncogenes are activated, while tumor suppressor are inhibi ted (3, 4) Although numerous therapeutic strategies have been developed, the 5-y ear survival of HCC still remained low (5) . Therefore, it is critical to understand the molecular mechanism of HCC and therefore to explore new potential therapeutic agents.
MiRNAs are a cluster of non-codi ng small RNAs, which approximately contains 22 to 25 nucleotide (6) . Through the interaction wi th the 3′-untranslated regions (3′-UTRs) of target mRNAs, miRNA may inhibit expression of the targeted genes or induce thei r degradation (7) . Findings have indicated that abnormal miRNA expression plays crucial roles in the development of cancer (8, 9) .
Among those miRNAs, miR-92a generally plays a promoting role in several types of human cancers; for example, by inhibiting p21, miR-92a promotes cell proliferation in cervical cancer (10) . By suppressing F-box and WD repeat-containing protein 7, miR-92a promotes osteosarcoma tumor growth (11) . By inhibiting KLF4, miR-92a promotes colorectal cancer cell proliferation and migration (12) . However, although it is reported that deregulation of miR-92a is implicated in HCC development (13) , but the underlying mechanism in HCC remains unclear.
The forkhead box transcription factor A family contai ns FOXA1 (HNF3α), FOXA2 (HNF3β) and FOXA3 (HNF3γ) (14) . Among them, FOXA2 belongs to the hepatocyte nuclear factor family and is responsible for liver glucose homeostasis (15) . As reported, FOXA2 suppressed the HCC metastasis through inhibition of matrix metalloproteinas e-9 (16), but the mechanism for the regulation of FOXA2 was still unclear.
Materials and Methods

Cell culture
The human HCC cell line HepG2, Huh7 and Hep3B were obtained from the American Type Tissue Culture Collection (ATCC). Normal human hepatocyte L02 cells were purchased from the Shanghai Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China).
The above cells were cultured in D ulbecco's modified Eagle's medium (DMEM; Gibco, Carlsbad, CA, USA) wi th 10% fetal bovine s erum (FBS; Gibco, Uruguay), 100 mg/ml penicillin -Streptomycin (invitrogene), in a humidified atmosphere co ntaining 5% CO2 at 37 °C.
Reagents and Transfection
Synthetic miR-92a and the scrambled negative control RNA (miR-control) were purchased from (Genechem, Shanghai, China). All cells were cultured in 6-well plates.
Small interfering RNA (siRNA) sequence targeting human Foxa2 cDNA was synthesized from GenePharma in the RNA interference assay (Shanghai, China). The scrambled siRNA was used as a negative control (NC). When the cells growth reached to 70% confluent, Lipofectamine 2000 (Invitrogen) was used for transfection. Equal amounts of miR-92a or miR-control or relative plasmids were added to each well, 48 hr after transfection, the cells were harvested for qRT-PCR and western blotting.
RNA isolation and qRT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions, and cDNA was synthesized using the Primescript RT reagent (TAKARA, Dalian, China). Using oligo dT as primers, 1 μg of total RNA was reverse-transcribed to cDNA. RNeasy MinElute Cleanup Kit (Qiagen) and miRNeasy Mini Kit were used to extract the miRNAs according to the manufacturer's instructions.
Quantitative RT-PCR was performed on ABI 7500 Real-Time Sequence D etection System (Applied Biosystems) using SYBER Green Dye (Invitrogen), and GAPDH was used as an internal control using the 2-ΔΔCT method.
TaqMan miRNA (Applied Biosystems, Foster City, CA) probes were used to measure the miRNAs according to the manufacturer's instructions. In quantitative PCR, the rel ative levels of miRNAs were normalized to U6.
Luciferase reporter assay
The Dual Luciferase Reporter Assay System (Promega, USA) was used for luciferase reporter assay, for searching the target gene for miR-92a. The enti re 3′-UTR of human FOXA2 was amplified using PCR. The PCR product was inserted into the p-GL3 -reporter plasmid (Promega) and confi rmed by sequencing. The mutant of FOXA2 3′-UTR (from CCCACC to CCCAGC) was used to test the binding specificity, and FOXA2 3′-UTR mutant form was also inserted into the equival ent luciferas e reporter. HepG2 cells were cultured in 24-well plates. The plasmids and 100 pmol of miR-92a or miR-control were co-transfected with the Renilla plasmid using Lipofectamine 2000 (Invitrogen) into HepG2 cells, and 48 hr post-transfection, the cells were assayed. The promoter activity was calculated as firefly /Renilla.
Western blotting
All cells were lysed using RIPA Lysis buffer (Beyotime, China), which were supplemented wi th a protease inhibitor cocktail (Roche) on ice for 30 min. After centrifuged for 15 min at 4°C, (12000 g), the supernatant was collected. A BCA protei n assay kit (Thermo Scientific, USA) was used to calculate the protein concentration. The membranes were blocked in 5% nonfat milk in TBST and incubated wi th the appropriate primary antibodies overnight at 4 °C. Followed by washing with TBST for 5 times, the membranes were incubated wi th goat anti-rabbi t or goat anti-mouse secondary antibodies at room temperature. Finally, immunoreactive bands were measured using the Bandscan ImageJ software.
Cell proliferation assay
MTT assay was us ed to assess cell proliferation. Briefly, 2,500 trans fected HepG2 cells were seeded in triplicate i n 96-well plates per well in 100 μl of culture medium. Afterwards, 20 μl of MTT reagent was added to each well 12, 24, 36, 48, 72, and 96 hr after transfection and then inc ubated for 4 hr according to the manufacturer's instructions. To terminate the reaction, 100 μl of DM SO was added in each well. The absorbance was meas ured at 570 nm on an ELISA plate reader (Biotek Ins truments, Inc, USA). Each assay was performed in triplicate.
Cell cycle analysis
Cells were s eeded into 6-cm diameter plates and treated with 10% FBS. 48 hr after transfection, 1 × 10 6 cells in each group were harv ested, and after washing with phos phate buffered saline (PBS) for 3 times, the cells were fixed with 70% ice-cold ethanol for 24 hr at 4 °C. Then, a mixture contai ning 0.5 ml propi dium iodide, 0.5 mg/ml ribonuclease A and 0.2% Triton X-100 were us ed to incubate with the cells for 30 min. Cell cycle distribution was measured using BD C6 flowcytometry (BD Biosciences, San Jose, CA, USA).
Cell invasion assay
Cell invasion was determined using 24-well transwell boyden chamber (8.0 μm pore size with polycarbonate membrane) (Cos tar, USA) according to the manufacturer's instructions. The upper chamber was covered with 100 μl diluted Matrigel (1 mg/ml) (BD Company) and incubated at 37 °C in 5% CO2 for 1 hr. Cells transfected wi th relative constructs were sus pended in 500 μl DMEM medium without FBS and added to the upper compartment (1 × 10 4 cells/well). Then, 600 μl of DMEM with 10% FBS was added to the lower chamber. Following 24 hr incubation, the non-invading cells were scraped off gently using cotton-ti pped swabs. Cells that had entered the lower chamber were stai ned with 0.1% crystal violet and 2% ethanol for 15 min at room temperature and photographed using a photomicroscope (BX51 Olympus, Japan), 5 fields per chamber and then counted blindly.
Statistical analysis
SPSS version 17.0 software (SPSS, Inc. Chicago, IL, USA) was used for statistical analysis. Quanti tative RT-PCR, cell proliferation assay, invasion assay and the luciferase reporter were performed i n triplicate. The data were shown as the mean±SD, of at least three independent experiments. P<0.05 was considered as statistically significant. Student's t test was used for determining statistical significance.
Results
The expression of miR-92a was up-regulated in human HCC cell lines To investigate the possible role of miR-92a in HCC, qRT-PCR was used to analyze the expression of miR-92a in three HCC cell lines, HepG2, Huh7 and Hep3B. Compared with the normal human hepatocy te L02 cells, miR-92a expression was significantly up-regul ated ( Figure 1A ).These data indicated that the hi gher expression of miR -92a may contribute to the HCC malignant phenotypes. As a result, we performed miR -92a gain-offunction and loss-of-function studies in HepG2 cells and Huh7 cells in the following research. As shown in Figure 1B , qRT-PCR analysis showed that the expression level of miR-92a was obviously decreased in the HepG2 and Huh7 cells transfected with anti-miR92a compared with miR-NC cells. Subsequently, the result of overexpression assay that was performed in HepG2 and Huh7 cells transfected with miR-92a or the control mimics showed that the expression of miR-92a was obviously increased in miR-92a mimic-transfected cells ( Figure 1C ).
miR-92a promoted cell growth an d prolif eration of HCC cells
We further inves ti gated the rol e of miR -92a i n the regul ation of HCC cell growth and proliferation. MTT assay was used in the HepG2 cells transfected with the mi R-92a or control mimics, or cells transfected with anti-mi R-92a or miR-NC. The res ults showed that ov erexpression of miR -92a significantly increas ed HepG2 cell growth, while the knockdown of miR-92a coul d remarkably inhibit the growth rates (Fi gure 2A). Similar resul t was also shown in the Huh7 cells ( Figure 2B ). Further, cell cycle distributi on was performed usi ng flowcytometry in HepG2 and Huh7 cells ( Figure 2C and 2D). The function of mi R-92a was meas ured, and compared with the control group cells. In the miR-92a transfection cells, there was a substantial increase in S phase and a decrease in G1 phase populations, while knockdown of miR-92a blocked the progression of cell cycle from the G1 phase to S phas e. The above data s ugges ted that Foxk2 miR-92a promoted cell growth and proliferatio n of HCC cells through induction of G1 arrest.
miR-92a promoted cell invasion of HCC cells
Transwell invasion assay was used to examine the effect of miR-92a on HepG2 cell motility. The invasion ability of HepG2 cells was significantly increased in the miR-92a transfection group compared with cells transfected with the miR-control, while in the cells transfected with anti-miR-92a, the invasion ability was obviously suppressed compared with the miR-NC ( Figure 3A and 3B) . Similarly, miR-92a was able to significantly promote Huh7 cells motility ( Figure 3C ). These above data suggested that miR-92a could remarkably promote both proliferation and invasion of HepG2 and Huh7 cells.
Validation of FOXA2 as a direct target of miR-92a
TargetScan 6.2 (http://www.targetscan.org) was used to screen the potential target of miR-92a, and FOXA2 was considered as a target with potenti al mi R-92a-binding si tes. According to the bioinformatics data, sev eral potenti al targets for miR-92a were identified. Howev er, the bi ndi ng of FOXA2 was wi th hi gh confident scores. In li ght of the previous observation that FO XA2 was implicated i n the dev elopment and progression of HCC, we focus ed our study on FO XA2 (Fi gure 4A). Luciferase activity assay was performed i n HepG2 cells, and the results showed that miR -92a significantly inhibi ted the wild ty pe 3 ′-UTR of FOXA2 luciferase activity, but not the mutant (M ut) type. The similar res ult was also shown i n the Huh7 cells ( Figure 4B and 4C) . Furthermore, wes tern blot was us ed to meas ure the protei n lev el of FOXA2, and we found that the miR -92a si gnificantly inhibi ted FO XA2 expression in HepG2 cell transfected wi th mi R-92a compared with control mimic ( Figure 4D ). Consistently, overexpression of miR-92a significantly suppress ed FOXA2 protein levels in Huh7 cells ( Figure 4E ). These data indicated that FOXA2 is a target of miR-92a.
MiR-92a in duces HCC proliferation an d invasion through the inhibition of FOXA2 expression
Since FOXA2 was a direct target of miR-92a, we further studied whether FOXA2 was involved in the function of miR-92a. We first established the FOXA2 overexpression plasmid and transfected into HepG2 or Huh7 cells, as measured by qRT-PCR. The FOXA2 mRNA level was significantly increased in FOXA2 overexpression groups compared with the vector groups ( Figure 5A ). MTT assay in HepG2 cells, cotransfected either with miR-92a and a FOXA2 overexpression plasmid, or control mimics, or miR-92a and pcDNA3.1, or pcDNA3.1-FOXA2 showed that FOXA2 restoration obviously reversed the promotion effects of miR-92a ( Figure 5B) ; similar results were also observed in the Huh7 cells ( Figure 5C ). Transwell assay showed that overexpression of FOXA2 dramatically reversed the effects of miR-92a on HCC invasion ability ( Figure 5D) ; similar results were also found in Huh7 cells ( Figure 5E ). The above data suggested that miR92a functions as partially driving factor by targeting FOXA2. 
Discussion
Increasing evidence shows that miRNAs pl ay essenti al roles duri ng cancer progression, such as proliferation, metas tasis, and angiogenesis (17, 18) . HCC, the mos t common liver cancer, has been reported to have a v ariety of aberrantly altered miRNAs, many of which function as oncogenes or tumor suppressors (19) , (20) .
As previously (21) reported, microRNA-24 lev el is increas ed in HCC and is positiv ely correlated with HCC prognosis and tumori genesis. As well, it is reported that microRNA-30d promoted cancer invasion and metastasis by targeting Galphai2 in HCC (22) , while microRNA-422a was si gnificantly down-regulated i n HCC sampl es via targeti ng forkhead box G1, FOXQ 1, and FO XE1 i n the regulation of HCC dev elopment (23) . Also, i t is reported that miR-135b was usually amplified and up-regul ated i n HCC tissues and promoted HCC cells invasion and metastasis in vi tro and in vivo (24) . Moreover, fi ndi ngs have s hown that miR-522 contributed to HCC cells proliferation by regulation of DKK1 and SFRP2 (25) , while microRNA-141 inhibited HCC cells proliferation and inv asion and promoted apoptosis by targeting hepatocyte nuclear factor-3β (26) . But, the function of miR -92a in hepatocellular carcinoma is still unclear.
In this s tudy, we found that miR-92a was us ually up-regul ated i n the HCC cell lines. Knockdown of miR-92a suppressed HCC cell proliferation and invasion, while overexpression of miR -92a showed the opposite tendency. FO XA2 was identified as a target of miR-92a in HCC cells. As shown from the luciferas e reporter assay, mi R-92a could bi nd to the 3'UTR of FO XA2. RT-PCR and western blot s howed that miR-92a regul ates FOXA2 expression through leading to the mRNA degradation. Restoration of FOXA2 coul d partially reverse the oncogenic effects of miR-92a. The above data sugges t that miR -92a might function as an oncogene through targeti ng FOXA2. As known, HCC should be characterized as a multi -stage process, which contai ns numerous gene expression alterations (27, 28) . Discovery of critical miRNAs i n modul ati ng gene expression has not only changed our concept of tumori genesis regulation, but has also offered opportuni ties for desi gni ng new anticancer strategies and therapi es (29) . In the future, more targets of miR-92a s houl d be found and more evidence s houl d be provided. The underlying on the molecular mechanisms may provide potential targets for HCC treatment.
Conclusion
We demonstrated that miR -92a may pl ay a critical role in HCC proliferation and invasion. By regulating the repression of FOXA2, miR-92a may serve as a novel therapeutic target.
